Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men

Morbidity and Mortality Weekly Report

Volumn 60, Issue 3, 2011, Pages 65-68

  Smith, D K ^a   Grant, R M ^a   Weidle, P J ^a   Lansky, A ^a   Mermin, J ^a   Fenton, K A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; UNSAFE SEX;

ADENINE; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PHOSPHONIC ACIDS; UNSAFE SEX;

EID: 79251646972     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Hall HI, Song RG, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520--9.
2. CDC. Diffusion of Effective Behavioral Interventions. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.effectiveinterventions.org/en/home.aspx. Accessed January 20, 2011.
3. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(No. RR-12).
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587--99.
5. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). Presented at the 18th International AIDS Conference, Vienna, Austria, July 2010.
6. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257--64.
7. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR 2006;55(No. RR-16).
8. Food and Drug Administration. Truvada: highlights of prescribing information (package insert). Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021752s017lbl.pdf. Accessed January 20, 2011.
9. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582--92.
10. AIDS Vaccine Advocacy Coalition. Global advocacy for HIV prevention. Ongoing PrEP trials. Available at http://www.avac.org/ht/d/sp/i/3507/pid/3507. Accessed January 20, 2011.